Neogen Corp key statistics and ratios
In fiscal 2026, Neogen Corp had return on equity of -0.4%, an operating margin of -2.5%, debt equal to 38.2% of equity and a current ratio of 3.82. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2010May 2010 | 2011May 2011 | 2012May 2012 | 2013May 2013 | 2014May 2014 | 2015May 2015 | 2016May 2016 | 2017May 2017 | 2018May 2018 | 2019May 2019 | 2020May 2020 | 2021May 2021 | 2022May 2022 | 2023May 2023 | 2024May 2024 | 2025May 2025 | 2026May 2026 | LTMAug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 51.9% | 50.8% | 50.2% | 52.8% | 49.6% | 49.3% | 47.6% | 47.1% | 46.8% | 46.3% | 46.9% | 45.9% | 46.1% | 49.4% | 50.2% | 47.1% | 46.9% | 47.4% |
| Operating margin | 19.1% | 20.8% | 18.3% | 19.6% | 17.5% | 18.8% | 17.6% | 18.1% | 17.6% | 16.4% | 16.1% | 15.8% | 11.1% | 4.6% | 6.3% | −118.6% | −2.5% | −0.8% |
| Net margin | 12.5% | 13.2% | 12.2% | 13.1% | 11.4% | 11.8% | 11.4% | 12.2% | 15.9% | 14.5% | 14.2% | 13.0% | 9.2% | −2.8% | −1.0% | −122.1% | −0.9% | −6.3% |
| Free-cash-flow margin | 16.1% | 12.2% | 11.3% | 8.5% | 4.1% | 12.1% | 6.6% | 12.8% | 12.1% | 11.9% | 14.8% | 11.6% | 8.3% | −3.0% | −8.2% | −5.2% | 3.7% | 5.6% |
| Return on equity | 11.4% | 13.4% | 11.0% | 11.4% | 10.0% | 10.2% | 9.7% | 10.0% | 12.2% | 10.0% | 8.7% | 7.8% | 5.6% | −1.1% | −0.3% | −41.9% | −0.4% | −2.7% |
| Return on assets | 9.7% | 11.4% | 9.6% | 10.0% | 8.9% | 9.1% | 8.7% | 9.0% | 11.0% | 9.2% | 8.0% | 7.1% | 5.1% | −0.8% | −0.2% | −27.3% | −0.2% | −1.7% |
| Asset turnover | 0.78 | 0.86 | 0.78 | 0.77 | 0.78 | 0.77 | 0.76 | 0.73 | 0.69 | 0.63 | 0.56 | 0.55 | 0.55 | 0.30 | 0.20 | 0.22 | 0.26 | 0.27 |
| Current ratio | — | 6.88 | 7.20 | 9.51 | 7.56 | 9.08 | 8.68 | 8.14 | 9.71 | 11.75 | 11.08 | 11.03 | 8.05 | 4.03 | 3.82 | 3.32 | 3.82 | 3.90 |
| Debt to equity | 0.0% | 2.4% | 1.2% | 0.8% | 0.6% | — | 0.6% | 0.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 28.7% | 28.7% | 43.6% | 38.2% | 37.1% |
| Interest cover (operating income ÷ interest) | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.4x | 1.4x | n/m | n/m | — |
| Effective tax rate | 35.9% | 35.2% | 33.8% | 34.3% | 34.9% | 35.5% | 34.2% | 34.0% | 14.0% | 17.5% | 17.7% | 19.1% | 19.8% | — | — | — | — | — |
| R&D as % of revenue | 4.5% | 4.0% | 3.6% | 3.7% | 3.4% | 3.4% | 3.1% | 2.9% | 2.7% | 3.1% | 3.5% | 3.5% | 3.2% | 3.2% | 2.4% | 2.4% | 2.1% | 2.2% |
| Capital spending as % of revenue | 3.9% | 4.5% | 0.8% | 4.3% | 4.7% | 3.4% | 4.4% | 4.1% | 5.3% | 3.5% | 5.8% | 5.7% | 4.6% | 8.0% | 12.1% | 11.7% | 5.9% | 4.0% |
| Free cash flow ÷ net income | 128.7% | 92.2% | 92.3% | 65.0% | 36.0% | 101.9% | 57.7% | 104.3% | 76.3% | 81.7% | 104.0% | 89.3% | 90.3% | — | — | — | — | — |
| Dividends and buybacks ÷ free cash flow | — | — | — | — | — | — | — | — | — | 6.4% | — | — | — | — | — | — | — | — |
| Quarter | 2025 Q2Nov 2024 | 2025 Q3Feb 2025 | 2025 Q4May 2025 | 2026 Q1Aug 2025 | 2026 Q2Nov 2025 | 2026 Q3Feb 2026 | 2026 Q4May 2026 | 2027 Q1Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 49.0% | 49.9% | 41.2% | 45.4% | 47.5% | 46.9% | 47.8% | 47.4% |
| Operating margin | −197.8% | 2.4% | −271.0% | −7.7% | −2.4% | −1.6% | 1.4% | −0.8% |
| Net margin | −197.3% | −4.9% | −271.5% | 17.4% | −7.1% | −8.0% | −5.0% | −5.3% |
| Free-cash-flow margin | 10.0% | −6.1% | 0.1% | −6.3% | 3.5% | 5.2% | 11.6% | 2.1% |
| Current ratio | 3.77 | 3.91 | 3.32 | 3.58 | 3.91 | 3.92 | 3.82 | 3.90 |
| Debt to equity | 33.3% | 33.5% | 43.2% | 37.4% | 37.7% | 37.7% | 37.9% | 37.1% |
| R&D as % of revenue | 2.2% | 2.0% | 2.8% | 2.4% | 2.0% | 1.8% | 2.2% | 2.9% |
Financial health
- Short-term assets cover short-term liabilities $582m of assets due within a year against $150m of liabilities due within a year.
- Short-term assets cover long-term liabilities $582m short-term assets against $1.1bn of longer-dated liabilities.
- More cash than debt $172m of cash against $774m of debt.
- Debt below 40% of shareholders' equity Debt is 37% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt $85m of operating cash flow against $774m of debt.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Weak moat
How hard Neogen's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 4 / 20
Cash operating profit has been a median 4.9% of total assets over 10 years.
- Pricing power 16 / 20
Gross margin has been a median 46.6%, moving by 1.3 percentage points (standard deviation) across 10 years.
- Durability 3 / 20
Operating margin has been a median 11.9%; its worst year was -121.7%.
- Cash conversion 10 / 20
Free cash flow was positive in 6 of 10 years, at a median 8.5% of revenue.
- Discipline 10 / 20
The diluted share count rose 102.5% over five years; stock-based pay has been a median 1.4% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Inspire Medical Systems, Inc. statistics
- Varex Imaging Corp statistics
- Alphatec Holdings, Inc. statistics
- Orthofix Medical Inc. statistics
- Irhythm Holdings, Inc. statistics
Head to head: INSP vs NEOGNEOG vs VREXATEC vs NEOG
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies